| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$12,239,492 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$12,239,492 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-04 |
4 |
OE |
$86.52 |
$365,117 |
D/D |
4,126 |
35,679 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-03 |
4 |
AS |
$229.35 |
$953,861 |
D/D |
(4,126) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-03 |
4 |
OE |
$86.52 |
$365,117 |
D/D |
4,126 |
35,679 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-07-31 |
4 |
AS |
$88.76 |
$375,238 |
D/D |
(4,200) |
0 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-27 |
4 |
AS |
$287.23 |
$1,218,449 |
D/D |
(4,238) |
32,038 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-26 |
4 |
AS |
$425.70 |
$1,804,542 |
D/D |
(4,239) |
25,813 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-18 |
4 |
AS |
$229.22 |
$995,949 |
D/D |
(4,312) |
49,687 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-02 |
4 |
OE |
$86.52 |
$403,183 |
D/D |
4,660 |
70,357 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-02 |
4 |
AS |
$247.73 |
$1,171,842 |
D/D |
(4,660) |
65,697 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-13 |
4 |
AS |
$296.44 |
$1,434,126 |
D/D |
(4,798) |
54,396 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-07-31 |
4 |
OE |
$59.55 |
$297,750 |
D/D |
5,000 |
5,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-09-19 |
4 |
AS |
$99.75 |
$511,250 |
D/D |
(5,000) |
0 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-09-19 |
4 |
OE |
$59.55 |
$297,750 |
D/D |
5,000 |
5,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2015-12-01 |
4 |
AS |
$131.00 |
$655,000 |
D/D |
(5,000) |
75,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2015-12-01 |
4 |
OE |
$72.14 |
$360,700 |
D/D |
5,000 |
80,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-11 |
4 |
AS |
$210.42 |
$1,112,274 |
D/D |
(5,283) |
53,098 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-19 |
4 |
AS |
$186.81 |
$1,051,716 |
D/D |
(5,624) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-13 |
4 |
D |
$298.26 |
$1,786,577 |
D/D |
(5,990) |
59,194 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-24 |
4 |
D |
$227.86 |
$1,375,819 |
D/D |
(6,038) |
43,649 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-17 |
4 |
D |
$211.75 |
$1,321,320 |
D/D |
(6,240) |
46,858 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-14 |
4 |
AS |
$295.79 |
$1,911,108 |
D/D |
(6,398) |
47,998 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-02-13 |
4 |
AS |
$87.68 |
$561,415 |
D/D |
(6,403) |
106,011 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-02-12 |
4 |
AS |
$149.23 |
$965,671 |
D/D |
(6,403) |
69,999 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,114 |
52,832 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-04-28 |
4 |
OE |
$63.14 |
$473,550 |
D/D |
7,500 |
113,511 |
0 |
- |
|
157 Records found
|
|
Page 5 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
